Brian O’Sullivan is a Professor in the Department of Radiation Oncology and in the Department of Otolaryngology / Head and Neck Surgery at the University of Toronto. He holds the Bartley-Smith/Wharton Chair in Radiation Oncology in the Department of Radiation Oncology at the Princess Margaret Hospital. He received his medical degree from the National University of Ireland at University College Dublin in 1976, and completed internship and general internal medicine at St. Vincent’s Hospital in Dublin, and a fellowship in medical oncology, and a residency and clinical fellowship in radiation oncology at Princess Margaret Hospital.
Professor O’Sullivan is the immediate past-Chair of the Head and Neck Oncology Committee of the Canadian Clinical Trials Group (CCTG) and current co-Chair of the US NCI Head and Neck Steering Committee of the Coordinating Center for Clinical Trials, CTEP. He is the recipient of numerous international awards such as the O.Harold Warwick Prize, the ESTRO Honorary Membership Award, the Fellow of ASTRO Award, the Juan Del Regato Gold Medal, the Inaugural Stiefel Lectureship and the Gilbert Fletcher Distinguished Professor Lecturer at MD Anderson Cancer Centre, and the Ira Spiro Distinguished Memorial Lecturer Award at Harvard Medical School.
He has published almost 350 peer reviewed papers, more than 50 book chapters, and written or edited 6 oncology textbooks. He is a Commissioner, International Commission on Radiation Units & Measurements (ICRU). He is a member of the TNM Committee of the Union for International Cancer Control (UICC), Chair of the UICC Prognostic Factors Sub-Committee, Editor-in-Chief of the UICC Manual of Clinical Oncology, and the UICC liaison to the American Joint Committee on Cancer (AJCC) for head and neck cancer, and bone and soft tissue sarcoma.
His interests include the biology and clinical behavior of sarcoma and head and neck cancer, cancer staging and prognostic factor, risk stratification and treatment optimization, clinical trial and translational research, quality improvement and global cancer control.